15 active trials 0 recruiting 6 Phase 3 6 disease areas 2 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.
Primary and study completion pushed from Jan 31, 2027 to Apr 30, 2027
Acerta Pharma BVPhase 3 NCT03836261 Registry history of NCT03836261 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 3 | |
| Phase 1/2 | 3 | |
| Phase 2 | 3 | |
| Phase 3 | 6 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously… | Lymphoma, Mantle Cell | Active, Not Recruiting | 2026-10-08 |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-10-05 |
| NCT02477696 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-08-26 |
| NCT02475681 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-08-25 |
| NCT02970318 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-07-24 |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB… | Diffuse Large B-Cell Lymphoma | Active, Not Recruiting | 2026-06-25 |
| Phase 2 | ||||
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | Waldenström Macroglobulinemia (WM) | Active, Not Recruiting | 2026-09-14 |
| NCT02213926 | An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell… | Mantle Cell Lymphoma (MCL) | Active, Not Recruiting | 2026-08-04 |
| NCT02717611 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-03-25 |
| Phase 1/2 | ||||
| NCT02180711 | Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell… | Non Hodgkin Lymphoma | Active, Not Recruiting | 2026-09-28 |
| NCT02029443 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-05-05 |
| NCT02586857 | A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent… | Glioblastoma Multiforme | Active, Not Recruiting | 2026-03-25 |
| Phase 1 | ||||
| NCT02717624 | A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in… | Mantle Cell Lymphoma (MCL) | Active, Not Recruiting | 2026-07-14 |
| NCT03328273 | A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-07-14 |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2025-08-13 |
Chronic Lymphocytic Leukemia (CLL) (8) · Leukemia (8) · Mantle Cell Lymphoma (3) · Non-Hodgkin Lymphoma (2) · DLBCL (1) · Glioblastoma (1)